Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.
14C Custom Radiolabelling for pre-clinical ADME studies
14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)
GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance
Stable Labelling (13C, 2H, 15N) Internal Standards, Metabolites and Impurities
Stable Labelling 13C 2H 15N
GLP Analysis Certification and Problem Solving including GLP NMR
GEM FORLAB gives continuity to the experience of ABLE Biosciences as a global provider of scientific technology and services to the Life Science industry. It delivers solutions to companies of all size and shapes.
GEM FORLAB performs its activities by means of three technology areas:
Mass Spectrometry & Proteomics
Cell and Molecular Biology & Immunoassay
ABLE Biosciences is the Test Facility GLP certified for small and large molecules quantitative analysis in biological matrices by means of Mass Spectrometry, Immunometric assays and qPCR and it is included in OsSC register of Private Laboratories qualified to perform analysis on samples derived from drug clinical trials (phase I-II-III) in compliance with GCP.
The Chemistry Unit provides all essential components for early drug discovery such as synthesis of chemical intermediates, process impurities, reference compounds, drug metabolites, and pro-drug; lead generation and optimization; bioconjugate chemistry; targeted molecules for MRI and others Molecular Imaging techniques.
Activotec is a peptide synthesis Company specialising in peptide synthesizers, organic synthesizers and synthesis chemicals. Based in Cambridge, UK the Company develops and produces its own range of innovative peptide and organic synthesizers as well as providing the support and chemicals required for autmated and manual peptide synthesis.
Additionally Activotec provides a fast reliable custom peptide synthesis service delivery very high quality peptides at competitives prices. Activotec offers custom peptide services from small research scale to large scale manufacture with a full range of C and N terminal modifications.
AcZon is an Italian Company specializing in biotechnology that develops, produces and commercializes Silica Nanoparticles (Nanoprobes) - for diagnostic, clinical and research fields- as well as a range of conventional reagents optimized for various applications as, for example, fluorescent antibodies. People’s Health is the main focus and ultimate goal of our business; our “mission” is basically “To promote and providing Reagents for Diagnostics and Research, with very high brilliance and clarity of image, stability and sensitivity, by offering products and services that speed-up the diagnostic response time, provide a better service to the patient”. AcZon focuses with growing interest on the amazing potentials offered by combining chemistry, biotechnology and nanotechnology. Indeed, on this basis, AcZon has developed and optimized a line of new products (reagents for in vitro diagnostics and research) characterized by outstanding performances. Thanks to its team of researchers (chemists and biologists), all with considerable experience in the synthesis and functionalization of polymers and in the fields of immunology, proteins and bio-conjugations, AcZon has developed, and is now producing, a line of NanoProbes (proprietary technology), based on Silica NanoParticles (NPs), which are not exclusively suitable for diagnostic and clinical applications, but also for chemistry, pharmacy, agriculture and the environment
ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release' technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release' platform drives value through better products delivered with greater efficiency.
In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.
For more information on our services and Lock Release please visit